Artwork

Innehåll tillhandahållet av Talking About Tumors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Talking About Tumors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

02_02 Chemotherapy Options and Bisphosphonates in Early Breast Cancer

25:09
 
Dela
 

Manage episode 343735703 series 3335024
Innehåll tillhandahållet av Talking About Tumors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Talking About Tumors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

1. First, second, and third generation chemotherapy regimens

2. Considerations for anthracyclines

3. Considerations for taxanes

4. Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

44 episoder

Artwork
iconDela
 
Manage episode 343735703 series 3335024
Innehåll tillhandahållet av Talking About Tumors. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Talking About Tumors eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

1. First, second, and third generation chemotherapy regimens

2. Considerations for anthracyclines

3. Considerations for taxanes

4. Adjuvant bisphosphonates

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Budd GT et al. J Clin Oncol. 2015;33(1):58-64. doi:10.1200/JCO.2014.56.3296

2. Citron ML et al. J Clin Oncol. 2003;21(8):1431-1439. doi:10.1200/JCO.2003.09.081

3. Anampa J, Makower D, Sparano JA. BMC Med. 2015;13(1). doi:10.1186/S12916-015-0439-8

4. Sparano JA et al. J Clin Oncol. 2015;33(21):2353-2360. doi:10.1200/JCO.2015.60.9271

5. Coleman R et al. Lancet. 2015;386(10001):1353-1361. doi:10.1016/S0140-6736(15)60908-4

6. Gray R et al. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4

7. Abe O et al. Lancet. 2005;365(9472):1687-1717. doi:10.1016/S0140-6736(05)66544-0

8. Albain K et al. Lancet. 2012;379(9814):432. doi:10.1016/S0140-6736(11)61625-5

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

44 episoder

Toate episoadele

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

Snabbguide